mAbXmise Diagnostic Kits
mAbXmise determines the plasma concentration of monoclonal antibodies prescribed as single or combination therapies at selected time points.
Promise Advanced Proteomics
Promise Proteomics was created in 2010 as a spin-off of CEA Grenoble (France). This medtech company is currently wholly owned by the Aguettant group and is directed by Dr Eric Rougemond. Since 2013, Chief Scientific Officer of Promise, Dorothee Lebert, has led ambitious and collaborative R&D programs which have allowed to develop the technology, on which the diagnostic kits for personalized medical applications are based. Capitalizing on its unique know-how in the production of internal standards for protein assays and its recognized expertise in mass spectrometry-based quantification methods, Promise Proteomics is placing its skills at the service of healthcare professionals through its mAbXmise kits.
Browse Products by Field
Promise Proteomics was created in 2010 as a spin-off of CEA Grenoble (France). This medtech company is currently wholly owned by the Aguettant group and is directed by Dr Eric Rougemond. Since 2013, Chief Scientific Officer of Promise, Dorothee Lebert, has led ambitious and collaborative R&D programs which have allowed to develop the technology, on which the diagnostic kits for personalized medical applications are based. Capitalizing on its unique know-how in the production of internal standards for protein assays and its recognized expertise in mass spectrometry-based quantification methods, Promise Proteomics is placing its skills at the service of healthcare professionals through its mAbXmise kits.
Contact Promise Advanced Proteomics
7, parvis Louis Néel • BHT 52 A • CS 20050 38040 Grenoble Cedex 9 • FRANCE PHONE: +33 4 38 02 36 50
Website link